BioCryst Pharmaceuticals | BCRX - Sales Revenues

Stock Price
8.49
Daily Change
-0.08 -0.93%
Monthly
36.06%
Yearly
5.47%
Q1 Forecast
8.48

BioCryst Pharmaceuticals reported $-86.95M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Chugai Pharma JPY 346.3B 13.12B Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novavax USD 84.51M 330.97M Sep/2024
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025